Evidence map›Paper›PMID 41559759›Full record

ReviewMolecular cancer2026

Notch signaling in the tumor microenvironment: recent advances and targeted therapeutics.

Di Chen, Xinyu Gu, Jingdian Liu, Lixia Xu, Zi Ye, Peng Gao, Hongjiang Li, Henan Jiao, Peidong Liu, Guihong Li and 10 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Di Chen *Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Xinyu Gu *Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Jingdian Liu *Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Lixia Xu *Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Zi YeDepartment of Scientific Research, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Peng GaoDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Hongjiang LiDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Henan JiaoDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Peidong LiuDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Guihong LiDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Yazhou MiaoDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Changhe PangDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Bin YuDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Beibei NieDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Jing YanDepartment of MRI, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Dongming YanDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Xuqiang ZhuDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China. zhuxuqiang2007@163.com.
Yuting HeDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. fccheyt1@zzu.edu.cn.
Shen ShenDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China. shenshenay@163.com.
Xueyuan LiDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China. lixueyuan-82@163.com.

Funding

Henan Provincial Key Research and Development Special Project 251111313300the Excellent Young Talents Program in Health and Health Technology Innovation for Mid-career Professionals in Henan Province YQRC2025009the Henan Medical Science and Technique Foundation LHGJ20230239, LHGJ20250279 and SBGJ202402043the Henan Provincial Natural Science Foundation 242300421481 and 252300423196the National Natural Science Foundation of China 82401623, 82503252 and 82573653
6 · The paper itself

Abstract

The Notch signaling pathway, an evolutionarily conserved mechanism governing cell-cell communication, plays a pivotal and multifaceted role in shaping the tumor microenvironment (TME). This review provides a comprehensive overview of the core components and signaling mechanisms of the Notch pathway, encompassing both canonical and non-canonical signaling cascades. It further examines the dual functionality of Notch in tumorigenesis, functioning as either an oncogene or a tumor suppressor. A central focus of this review is the detailed investigation of the molecular mechanisms through which Notch signaling modulates key cellular constituents of the TME. Recent advances are systematically summarized, with emphasis on the role of Notch in regulating immune cell differentiation and function, angiogenesis, modulating cancer-associated fibroblasts, and maintenance of cancer stem cells. To facilitate clinical translation, the review highlights emerging therapeutic strategies targeting the Notch pathway, including γ-secretase inhibitors and modulators, monoclonal antibodies against ligands and receptors, small molecule inhibitors, and combination therapies integrating immune checkpoint inhibitors, chimeric antigen receptor immune cell therapy, cancer vaccines, and oncolytic viruses. Collectively, this work offers a systematic synthesis of recent progress in understanding the diverse roles of Notch signaling within the TME, emphasizing the therapeutic potential of modulating Notch signaling to reprogram the TME and enhance anti-tumor immunity.

Indexed as

NeoplasmsReceptors, NotchSignal TransductionTumor MicroenvironmentAnimalsHumansMolecular Targeted TherapyReceptors, NotchCancer-associated fibroblastsImmune cellsImmunotherapyNotch signalingTumor microenvironment

Identifiers

PMID41559759
PMCPMC12952144

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.